ADDF and AFTD Partner to Support Wave Life Sciences’ FTD and ALS Clinical Program

ADDF and AFTD Partner to Support Wave Life Sciences’ FTD and ALS Clinical Program

AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF) announced today that they have partnered to support Wave Life Sciences’ FOCUS-C9 Phase 1b/2a clinical trial investigating WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD), as well as amyotrophic lateral sclerosis (C9-ALS).

The partnership provides an investment from ADDF and AFTD that will support the evaluation of fluid biomarkers, functional assessments, and digital biomarkers in FOCUS-C9, potentially leading to clinically meaningful endpoints to inform development of treatments for FTD.

“AFTD is proud to support, through the Treat FTD Fund, this innovative and potentially significant clinical trial,” said AFTD CEO Susan L-J Dickinson. “For so many people living with FTD, this trial represents hope for effective treatments and for making the journey easier for the next family facing this disease. Our ongoing collaborations with both ADDF and Wave Life Sciences point to a future free of this disease, and we are grateful to all the clinical investigators and persons diagnosed with FTD who will participate in this important research.”

Klicka här att läsa mer.

Hållas informerad

color-icon-laptop

Registrera dig nu och håll koll på det senaste med vårt nyhetsbrev, evenemangsvarningar och mer...